Go Pro
→ The dollar reset no one told you about (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
$20.68
+0.7%		$19.56
$5.68
▼
$23.19
$1.33B0.02862,398 shs349,103 shs
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
$11.09
-0.7%		$14.77
$1.69
▼
$23.57
$330.39M0.21738,213 shs251,371 shs
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
$12.97
-0.8%		$25.10
$12.87
▼
$39.89
$1.28B0.312.53 million shs2.23 million shs
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
$22.30
-0.1%		$21.82
$6.50
▼
$49.95
$1.32B1.711.03 million shs802,595 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
+0.69%-5.30%+0.98%+42.24%+223.46%
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
+2.38%-4.45%-26.27%-13.48%+517.13%
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
-3.97%-12.16%-50.66%-51.43%-54.93%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
-3.29%-11.08%-3.08%+48.60%-30.25%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
$20.68
+0.7%		$19.56
$5.68
▼
$23.19
$1.33B0.02862,398 shs349,103 shs
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
$11.09
-0.7%		$14.77
$1.69
▼
$23.57
$330.39M0.21738,213 shs251,371 shs
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
$12.97
-0.8%		$25.10
$12.87
▼
$39.89
$1.28B0.312.53 million shs2.23 million shs
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
$22.30
-0.1%		$21.82
$6.50
▼
$49.95
$1.32B1.711.03 million shs802,595 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
+0.69%-5.30%+0.98%+42.24%+223.46%
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
+2.38%-4.45%-26.27%-13.48%+517.13%
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
-3.97%-12.16%-50.66%-51.43%-54.93%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
-3.29%-11.08%-3.08%+48.60%-30.25%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
2.78
Moderate Buy$33.0059.57% Upside
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
2.86
Moderate Buy$31.00179.53% Upside
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
2.52
Moderate Buy$36.63182.43% Upside
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
2.91
Moderate Buy$43.3894.54% Upside

Current Analyst Ratings Breakdown

Latest QTTB, CGEM, VOR, and RARE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/16/2026
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
9/14/2026
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D+) ➝ Hold (C-)
9/14/2026
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$39.00 ➝ $40.00
9/7/2026
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
9/4/2026
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetNeutral$28.00 ➝ $19.00
9/4/2026
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$43.00 ➝ $32.00
9/3/2026
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeModerate Buy ➝ Hold
9/3/2026
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$77.00 ➝ $28.00
9/3/2026
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$58.00 ➝ $28.00
9/3/2026
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$49.00 ➝ $18.00
9/3/2026
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Neutral
(Data available from 9/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
N/AN/AN/AN/A$6.92 per shareN/A
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
$53.74M6.14$1.54 per share7.20$3.41 per share3.25
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
$673M1.90N/AN/A($0.83) per share-15.63
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
-$219.88M-$3.10N/AN/AN/AN/A-52.89%-48.18%11/5/2026 (Estimated)
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
$29.82M$3.003.70N/AN/AN/A50.17%29.49%11/12/2026 (Estimated)
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
-$575M-$5.84N/AN/AN/A-81.79%-1,024.42%-44.40%11/3/2026 (Estimated)
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/AN/AN/AN/AN/A

Latest QTTB, CGEM, VOR, and RARE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2026Q2 2026
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
-$0.69-$0.80-$0.11-$1.16N/AN/A
8/6/2026Q2 2026
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
-$0.7993-$0.81-$0.0107-$0.81$3.67 millionN/A
8/5/2026Q2 2026
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
-$0.46-$0.44+$0.02-$0.44$0.75 millionN/A
8/4/2026Q2 2026
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
-$1.22-$0.90+$0.32-$0.90$183.08 million$214.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
N/AN/AN/AN/AN/A
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
N/AN/AN/AN/AN/A
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
N/AN/AN/AN/AN/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
N/A
8.42
8.42
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
N/A
20.30
20.30
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
N/A
1.73
1.56
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
86.31%
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
31.32%
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
97.67%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
97.29%

Insider Ownership

CompanyInsider Ownership
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
8.60%
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
34.46%
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
5.20%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
0.27%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
10964.36 million58.82 millionOptionable
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
2229.77 million19.51 millionN/A
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
1,37198.59 million93.46 millionOptionable
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
7659.16 million59.00 millionN/A

Recent News About These Companies

Vor Biopharma Inc. (VOR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
September 9, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4944756-vor-biopharma-inc-vor-presents-at-citigroups-biopharma-back-to-school-summit-2026-transcript
Vor Biopharma (NASDAQ:VOR) Stock Price Down 5.4% - Should You Sell?
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-vor-biopharma-nasdaq-vor-stock-price-down-54-should-you-sell-2026-09-09/
97,722 Shares in Vor Biopharma Inc. $VOR Purchased by Bank of New York Mellon Corp
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-97722-shares-in-vor-biopharma-inc-vor-purchased-by-bank-of-new-york-mellon-corp-2026-09-09/
Vor Biopharma Completes Enrollment in Phase 3 Trial of Investigational Drug for Generalized Myasthenia Gravis
September 8, 2026  |  marketscreener.comM
Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis
September 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/08/3357492/0/en/vor-completes-enrollment-of-global-phase-3-upstream-mg-trial-and-expands-telitacicept-global-franchise-into-ocular-myasthenia-gravis.html
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/04/3356794/0/en/vor-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4.html
Braidwell LP Has $10.55 Million Stake in Vor Biopharma Inc. $VOR
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-braidwell-lp-has-1055-million-stake-in-vor-biopharma-inc-vor-2026-09-03/
Bank of America Corp DE Has $2.01 Million Stock Holdings in Vor Biopharma Inc. $VOR
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-has-201-million-stock-holdings-in-vor-biopharma-inc-vor-2026-09-03/
Vor Biopharma Inc. (NASDAQ:VOR) Given Average Recommendation of "Moderate Buy" by Brokerages
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-vor-biopharma-inc-nasdaq-vor-given-average-recommendation-of-moderate-buy-by-brokerages-2026-09-03/
Vor Biopharma (NASDAQ:VOR) Stock Price Up 6.2% - Time to Buy?
September 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-vor-biopharma-nasdaq-vor-stock-price-up-62-time-to-buy-2026-09-02/
Vor Bio To Participate in Upcoming September Conferences
September 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/01/3354086/0/en/vor-bio-to-participate-in-upcoming-september-conferences.html
Vor Biopharma Shares Drop After Q2 Results
August 11, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vor-biopharma-shares-drop-q2-140534024.html
Vor Biopharma: Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 11, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69277816-vor-biopharma-vor-bio-reports-second-quarter-2026-financial-results-and-provides-corporate-update-399.htm
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 3, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/03/3337912/0/en/vor-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4.html
Vor Biopharma: Vor Bio Appoints David Zaccardelli to Board of Directors
July 8, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-07/68970529-vor-biopharma-vor-bio-appoints-david-zaccardelli-to-board-of-directors-399.htm
Vor Bio Appoints David Zaccardelli to Board of Directors
July 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/07/3323613/0/en/vor-bio-appoints-david-zaccardelli-to-board-of-directors.html
Vor Biopharma: A Financed Autoimmune Pivot With More Substance Than The Market Realizes
July 7, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4920412-vor-biopharma-a-financed-autoimmune-pivot-with-more-substance-than-the-market-realizes
Vor Biopharma Stock Short Interest Report | NASDAQ:VOR | Benzinga
July 3, 2026  |  benzinga.comhttps://www.benzinga.com/quote/VOR/short-interest
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/02/3321604/0/en/vor-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4.html
Why Vor Biopharma (VOR) Is Up 24.5% After Broad FTSE Russell Index Inclusion And What's Next
June 30, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/why-vor-biopharma-vor-24-150826972.html
Vor Biopharma: Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
June 8, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-06/68709300-vor-biopharma-telitacicept-receives-nmpa-conditional-approval-for-the-treatment-of-iga-nephropathy-in-china-399.htm

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Scientist handles blood sample in lab, symbolizing early cancer detection.
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
By Bridget Bennett | September 6, 2026
Dell logo illuminated in a data center setting with a laptop and server racks visible nearby.
One of Trump's Favorite Stocks Just Reported Blowout Earnings
By Jessica Mitacek | September 3, 2026
Computer monitor on a desk displaying a candlestick stock price chart showing a decline followed by an upward rebound.
3 Contrarian Trades for a Market That Looks Too Hot
By Bridget Bennett | August 25, 2026
Illustration of a satellite beaming signal to a smartphone and cell tower above a city skyline at dusk.
Space Race Meets Ground Reality for Tower REITs
By Jeffrey Neal Johnson | September 1, 2026
A fighter jet with open engine panels sits on an aircraft carrier deck at sunset, with the ship's superstructure visible in the background.
Defense Stocks Are Pulling Back as Their Navy Tailwinds Get Stronger
By Jeffrey Neal Johnson | September 4, 2026
Cullinan Therapeutics stock logo

Cullinan Therapeutics NASDAQ:CGEM

$20.68 +0.14 (+0.69%)
As of 02:49 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Q32 Bio stock logo

Q32 Bio NASDAQ:QTTB

$11.09 -0.08 (-0.72%)
As of 02:49 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

Ultragenyx Pharmaceutical stock logo

Ultragenyx Pharmaceutical NASDAQ:RARE

$12.97 -0.10 (-0.77%)
As of 02:49 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

Vor Biopharma stock logo

Vor Biopharma NASDAQ:VOR

$22.30 -0.02 (-0.11%)
As of 02:49 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas